Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
The addition of daratumumab to lenalidomide and dexamethasone resulted in superior response rate and progression-free survival, as compared with lenalidomide and dexamethasone alone, at a cost of more frequent neutropenia and infusion reactions.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
6 October 2016
|
| In: |
The New England journal of medicine
Year: 2016, Volume: 375, Issue: 14, Pages: 1319-1331 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1607751 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1056/NEJMoa1607751
|
| Author Notes: | Meletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Mieczyslaw Komarnicki, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Steen Lisby, Nushmia Z. Khokhar, Lisa O’Rourke, Christopher Chiu, Xiang Qin, Mary Guckert, Tahamtan Ahmadi, Philippe Moreau |
| Summary: | The addition of daratumumab to lenalidomide and dexamethasone resulted in superior response rate and progression-free survival, as compared with lenalidomide and dexamethasone alone, at a cost of more frequent neutropenia and infusion reactions. |
|---|---|
| Item Description: | Gesehen am 07.11.2017 |
| Physical Description: | Online Resource |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1607751 |